United States: Should The Learned Intermediary Rule Apply To Prescription Marijuana?

Last Updated: June 18 2019
Article by James Beck

This year's annual DRI Drug & Medical Device Seminar marked a milestone of sorts, with a separate section on medical marijuana being offered for the first time. Regrettably, no free samples were on offer, although since the seminar was in Washington, DC it would have been perfectly legal (at least in terms of DC law) to augment the usual conference swag.

According to a source that appears to be accurate and unbiased, currently 33 states and DC have legalized the prescription of marijuana for medical purposes, and those states have well more than enough electoral votes to win a presidential election. This got us to thinking. Sooner or later somebody is going to sue some producer of medical pot alleging that some harmful effect caused by this "prescription drug" caused some sort of injury. What that injury might be, we have no idea. It's not addictive, and there is practically zero chance of overdose. But plaintiffs sue drug companies all the time, even if they haven't actually used the defendant's product. We call that "multidistrict litigation." So eventually we think it's inevitable that pot product liability will happen.

Which leads us to the question posed by this post: should the learned intermediary rule apply to marijuana when sold as a prescription drug?

We start with the purposes of the learned intermediary rule. Bexis' book, at §2.03[1] does as good a job as any at identifying them:

  • Warnings for prescription drugs are intended for the physician, whose duty it is to balance the risks against the benefits of various drugs and treatments and to prescribe them and supervise their effects.
  • The learned intermediary rule also ensures that product liability law respects the restricted distribution system imposed by federal law, under which prescription medical products may be obtained legally only through a prescribing physician.
  • Requiring that language used in prescription drug labeling be tailored to a lay audience, rather than learned intermediary physicians, would result in a loss of the clarity and precision needed to effectively communicate to practitioners. Patients are usually unable to evaluate the kind of technical information that doctors use to make prescription decisions.
  • The learned intermediary rule recognizes that physicians, not patients, make most prescription decisions in the context of a physician/patient relationship, so the rule preserves the physician/patient relationship from disruption by tort duties.
  • The medical decision to prescribe a particular product for a particular patient is individualized and requires an understanding of both the product being prescribed and the patient's medical history. Thus physicians are in the best position to exercise independent medical judgment that weighs the relative risks and benefits of prescription medical products, and then to explain those decisions to their patients.
  • In many instances manufacturers would find it impractical, or even impossible, to provide direct warnings to patients whose identities are unknown to them.

Id. at at pp. 2.03-1 to -14 & nn. 4-23.

Any discussion of the applicability of the learned intermediary rule to prescription pot must consider the extent to which these reasons – collectively sufficient to convince just about every court in the country in the context of ordinary prescription medical products – are applicable to medical marijuana.

The key difference, at least at the present time, is that medical marijuana is authorized only by the laws of the various states that have legalized it, and is not regulated by the FDA. The FDA's position is succinct, "The FDA has not approved marijuana as a safe and effective drug for any indication." As for state-licensed prescription pot:

The FDA is aware that several states have either passed laws that remove state restrictions on the medical use of cannabis and its derivatives or are considering doing so. It is important to conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. We welcome the opportunity to talk with states who are considering support for medical research of cannabis and its derivatives, so that we can provide information on Federal and scientific standards.

FDA, "FDA Regulation of Cannabis and Cannabis-Derived Products: Questions and Answers," available here. Perhaps at some point in the future, the FDA's role will change, but for present purposes we're considering only existing regulatory scheme, which is based entirely on state law.

The absence of the FDA has several implications for the learned intermediary rule. It immediately eliminates one of the rationales for the rule – conformance of the common law to the federally organized distribution system for prescription drugs – but that is probably the least salient issue. After all, if the states that have legalized prescription pot require a physician's prescription before anyone may acquire it, then the argument remains the same, simply with "state" replacing "federal."

The more important aspect of the FDA's absence from the equation has to do with what we consider the heart of the learned intermediary rule – that the intended audience for the warnings and most other information accompanying a prescription medical product consists of physicians and other professional health care providers. Given the professional level of the audience to which prescription medical product warnings are directed, they necessarily contain technical explanations that lay people would (at best) have trouble deciphering.

Well, what about prescription pot? What kind of warnings come with it? For us, that's the $64K question when it comes to the learned intermediary rule. If the states don't require a scientifically rigorous package insert for medical marijuana, then the learned intermediary rule is unlikely to apply. There would be no need for an intermediary, learned or otherwise, in that situation. So it comes down to what individual states actually require. There certainly could be warnings – we think, anyway – since we found this article, "Expert-Recommended Warnings for Medical Marijuana," online (though we didn't spend the $43 they wanted to buy it). There's another decent set of warnings at rxlist. However, we've seen no indication that any state requires warnings like this for their medical marijuana.

We Googled "warnings on medical marijuana" to get a feel for what warnings are actually given and came across statements like this: "[T]here are significant health risks associated with using cannabis and cannabinoids[, y]et none of the 33 states that have legalized medical marijuana, or the 10 states that have legalized recreational use, gives adequate warnings of those risks." Or this: "state politicians have given in to populism and the weed industry by ignoring science and allowing the sale of marijuana products with only the weakest of warning labels." Indeed, you can buy rolls of prescription pot "warning labels" on Amazon, with none of them being more than one paragraph long. That appears to be because most state-required warnings are minimal. In Pennsylvania, for example:

(c) The dispensary shall inspect the label to ensure that the label:

* * * *

(5) Contains the following warning stating:

This product is for medicinal use only. Women should not consume during pregnancy or while breastfeeding except on the advice of the practitioner who issued the certification and, in the case of breastfeeding, the infant's pediatrician. This product might impair the ability to drive or operate heavy machinery. Keep out of reach of children.

28 Pa. C.S.A. §1161.28. Other states mandate even less. See 8 Ill. Admin. C. §1000.420.

Another thing to consider in the learned intermediary rule context is the so-called "mass immunization" exception. See Bexis' book, at §2.03[3][b]. While created in response to the mass polio vaccinations of the 1960s, it extends beyond that precise set of facts. The Third Restatement requires, for the rule to apply, that there be "prescribing and other health-care providers who are in a position to reduce the risks of harm in accordance with the instructions or warnings." Restatement (Third) of Torts, Products Liability §6(d)(2).

Subsection (d)(2) recognizes that direct warnings and instructions to patients are warranted for drugs that are dispensed or administered to patients without the personal intervention or evaluation of a health-care provider. . . . When a manufacturer supplies prescription drugs for distribution to patients in this type of unsupervised environment, if a direct warning to patients is feasible and can be effective, the law requires measures to that effect.

Id., comment e. Thus, another criterion to consider is how a particular patient was actually prescribed purportedly harmful marijuana. Was the patient actually seen by a doctor? If so, what was the quality of their interaction? When a patient can obtain prescription pot "in a matter of minutes," as is apparently the case in California, then the chances of the manufacturer of the weed being able to rely on the learned intermediary rule goes down substantially.

Based on what we've seen to date, we don't think that it is likely that the learned intermediary rule will apply to medical marijuana, at least as long as the only product warnings appear to be directed primarily to consumers rather than health care providers. Further, where prescriptions are given out like candy (or, at least like Alice B. Toklas brownies) then the Restatement §6(d)(2) exception to the rule is likely to apply.

That is as it should be. The learned intermediary rule is for bona fide prescription medical products. Unless and until medical marijuana is treated – and labeled − as such, the rule doesn't apply. Further, attempts to assert it in the context of medical marijuana would probably do harm to the rule's current wide acceptance.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions